Mathai Mammen
@mmammen
CEO and Chairman Designate, FogPharma. prior Exec Comm JNJ, R&D, SVP R&D, Merck, founder SVP R&D Theravance Biopharma (TBPH), Innoviva (INVA)
ID:16174689
07-09-2008 22:29:45
201 Tweets
1,5K Followers
347 Following
Biotech is entering the hard work phase of immuno-oncology - great conversation with Mathai Mammen on precision medicine, the pharma to biotech transition, and more. The BioCentury Show, via BioCentury. biocentury.com/article/647820…
We needed some good news for this vaccine. This is it.
No sign a booster vs Delta is necessary (study is limited by small number of participants)
Financial Times by Nikou Asgari